Results 121 to 130 of about 5,953 (226)
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan [PDF]
, 2021 Pin‐Nan Cheng, Lein‐Ray Mo, Chun‐Ting Chen, Chi-Yi Chen, Chung‐Feng Huang, Hsing‐Tao Kuo, Gin‐Ho Lo, Kuo‐Chih Tseng, Yi‐Hsiang Huang, Chi‐Ming Tai, Cheng‐Yuan Peng, Ming‐Jong Bair, Chien‐Hung Chen, Ming‐Lun Yeh, Chih‐Lang Lin, Chun‐Yen Lin, Pei‐Lun Lee, Lee‐Won Chong, Chao‐Hung Hung, Te Sheng Chang, Jee‐Fu Huang, Chi‐Chieh Yang, Jui‐Ting Hu, Chih‐Wen Lin, Chia‐Chi Wang, Wei‐Wen Su, Tsai‐Yuan Hsieh, Chih‐Lin Lin, Wei‐Lun Tsai, Tzong‐Hsi Lee, Guei‐Ying Chen, Szu‐Jen Wang, Chun‐Chao Chang, Sheng‐Shun Yang, Wen‐Chih Wu, Chia‐Sheng Huang, Kwok-Hsiung Chou, Chien‐Neng Kao, Pei‐Chien Tsai, Chen‐Hua Liu, Mei–Hsuan Lee, Chien‐Yu Cheng, Ming‐Chang Tsai, Chun‐Jen Liu, Chia‐Yen Dai, Han‐Chieh Lin, Jia‐Horng Kao, Wan‐Long Chuang, Ming‐Lung Yu, TACR investigators +49 moreopenalex +1 more sourceSofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [PDF]
, 2016 Afdhal, N, Agarwal, K, Asselah, T, Berg, T, Bourliere, M, Braeu, N, Brainard, DM, Conway, B, Cooper, C, Dvory-Sobol, H, Foster, GR, Gane, EJ, Gordon, SC, Han, L, Investigators, AA, Lawitz, E, Mangia, A, Mazzotta, F, McHutchison, JG, McNally, J, Mo, H, Osinusi, A, Patel, K, Pianko, S, Reau, N, Roberts, SK, Rosenberg, W, Ruane, P, Shiffman, ML, Stedman, CAM, Sulkowski, M, Thompson, A, Towner, WJ, Tran, TT, Wang, J, Zeuzem, S +35 morecore +1 more sourceSofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
, 2022 Benjamin Maasoumy, Patrick Ingiliz, Christoph D. Spinner, Christiane Cordes, Hans‐Jürgen Stellbrink, Julian Schulze zur Wiesch, Stephan Schneeweiß, Katja Deterding, Tobias Müller, Julia Kahlhöfer, Petra Dörge, Maria von Karpowitz, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg +14 moreopenalex +1 more sourceAnalysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors
Scientific ReportsResistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (or R30E)/A92K ...Ai Toyodome, Seiichi Mawatari, Hiromi Eguchi, Midori Takeda, Kotaro Kumagai, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Masanori Ikeda, Akio Ido +11 moredoaj +1 more source
